ClinicalTrials.gg
CompletedNCT03363269Updated Jun 4, 2019

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease

A Phase 2 interventional study of ID1201 in Alzheimer Disease, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 20 sites in Korea, Republic of. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Apr 2016, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.

Enrollment
95th of 157
116 · median 206
Started
2016
with 11 others
Phase 2
27 of 174
5 open now
Registered
93rd of 174
by date

Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 95th largest by enrollment of the 157 interventional ones that give a count, is one of 12 that started in 2016, is one of 27 in phase 2, and was the 93rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Alzheimer Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of ID1201 in patients with mild Alzheimer's disease

Read the detailed description

ID1201 is a fruit extract of Melia toosendan. ID1201 alleviates Alzheimer's disease-type pathologies and cognitive deficit through the various actions of its effective components such as α-secretase activation followed to Aβ reduction, RAGE inhibition, neuro-protection, and anti-inflammatory activities.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient diagnosed with dementia of Alzheimer's type according to criteria and probable Alzheimer's disease according to the NINCDS-ADRDA
  2. modified Hachinski Ischemia Scale score of less than or equal to 4
  3. score 16 to 26 and Clinical Dementia Rating-Global Scale score 0.5 to 1
  4. Amyloid postivie PET image (BAPL score 2 or 3)
  5. Patients who have not received AChE inhibitors or NMDA antagonist at least for 3 months prior to the screening visit

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed or accompanied with Dementia due to other Neurodegenerative disorders other than Alzheimer's disease
  2. Chronic alcohol and/or drug abuse within the past 5 years
  3. Subjects who have medical history of significant renal disease (ccr\<30ml/min) or hepatic disease( 3* \<= or AST)
  4. Has received choline agonists, anticholinergics, anticonvulsants, antidepressants, antipsychotic drugs, Ginko biloba extract, Vitamin E, hormone replacement therapy etc. in the previous 4 weeks
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    ID1201 100mg

    Drug: ID1201

  • Experimental
    ID1201 200mg

    Drug: ID1201

  • Experimental
    ID1201 400mg

    Drug: ID1201

  • Placebo comparator
    Placebo

    Drug: ID1201

Interventions

  • DrugID1201
06

What researchers measure

Primary outcomes

  1. Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) at 12 Weeks

    Time frame: Baseline, 12 weeks

07

Study locations

20 sites
  • Dong-A University Hospital
    Busan, Korea, Republic of
  • Changwon Fatima Hospital
    Changwon, Korea, Republic of
  • Kangwon National University Hospital
    Chuncheon, Korea, Republic of
  • Daegu Catholic University Medical Center
    Daegu, Korea, Republic of
  • Kyungpook National University Chilgok Hospital
    Daegu, Korea, Republic of
  • Yeungnam University Medical Center
    Daegu, Korea, Republic of
  • Daejeon Eulji Medical Center, Eulji University
    Daejeon, Korea, Republic of
  • Myongji Hospital
    Goyang, Korea, Republic of
  • Hanyang University Guri Hospital
    Guri, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Inha University Hospital
    Incheon, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam-si, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, Korea, Republic of
  • Ewha Womans University Mokdong Hospital
    Seoul, Korea, Republic of
  • Hanyang University Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • KunKuk University Hospital
    Seoul, Korea, Republic of
  • Ajou University Medical Center
    Suwon, Korea, Republic of
  • Pusan National University Yangsan Hospital
    Yangsan, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2018, 32 months.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 32 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 6, 2017
StartActual
Apr 12, 2016
Primary completionActual
Dec 31, 2018
CompletionActual
Apr 17, 2019
Last update
Jun 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03363269
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Apr 12, 2016
Primary completion
Dec 31, 2018
Completion
Apr 17, 2019
Last update
Jun 4, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion